Results 111 to 120 of about 30,754 (261)

Multitarget Regulatory Mechanisms and Research Advances of Plant‐Derived Bioactive Ingredients in Hypertension Prevention and Management

Phytotherapy Research, EarlyView.
Schematic overview of the multi‐target and multi‐pathway mechanisms of PDBI in the prevention and management of hypertension. ABSTRACT Hypertension remains a major global risk factor for cardiovascular diseases, yet current treatments face challenges such as suboptimal blood pressure control and inadequate organ protection.
Qiqi Deng, Yonglin Zhang, Jing Pan, Jing Luo, Hualin Sun, Chaonian Li, Li Li   +6 more
wiley   +1 more source

Defining HFpEF in rodents: a systematic review

AIMS: Heart failure (HF) with preserved ejection fraction (HFpEF) has become the most diagnosed HF subtype representing a major public health burden with poor clinical outcome. Available treatment options for HFpEF are limited; hence, more in-depth basic/
Schiattarella, Gabriele G., Hegemann, Niklas, Kuebler, Wolfgang M., Beyhoff, Niklas, Grune, Jana, Adrah, Yamen, Faidel, David, Kucherenko, Mariya M.   +7 more
core   +1 more source

Integrative Approaches in Cardiovascular Disease: The Role of Nutraceuticals in Heart Failure, Atrial Fibrillation, and Related Conditions

Phytotherapy Research, EarlyView.
Schematic representation of the shared pathophysiological mechanisms underlying heart failure (HF) and atrial fibrillation (AF), including inflammation, oxidative stress, endothelial dysfunction, and fibrosis. The figure highlights the clinical and mechanistic convergence of conventional pharmacological therapies and selected nutraceuticals in ...
Laura Beatrice Mattioli, Ivan Corazza, Roberta Budriesi, Luca Camarda, Maria Carelli, Alberto Spadotto, Igor Diemberger   +6 more
wiley   +1 more source

Non‐canonical PKG1 regulation in cardiovascular health and disease

British Journal of Pharmacology, EarlyView.
It is well established that the cyclic GMP‐dependent protein kinase I (PKG1) is canonically activated by cyclic guanosine monophosphate (cGMP), enabling its regulation of vascular tone, cardiac function and smooth muscle homeostasis. However, diverse non‐canonical stimuli of PKG1 have also been identified.
Jie Su, Joseph Robert Burgoyne
wiley   +1 more source

HFpEF

Journal of the American College of Cardiology, 2014
Maurer, Mathew S., Mancini, Donna
openaire   +1 more source

Iron deficiency in heart failure: Epidemiology, diagnostic criteria and treatment modalities

ESC Heart Failure, Volume 12, Issue 2, Page 723-726, April 2025.
Stephan von Haehling
wiley   +1 more source

Cardiac surveillance in immune checkpoint inhibitor therapy: Insights from the Essen Cardio‐oncology Registry

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy, offering improvements in survival across various malignancies. However, their toxicities pose a major challenge for cardio‐oncology units. Despite their growing importance, data on effectiveness of such specialized units in mitigating ICI‐associated ...
Elias Haj‐Yehia, Lisa Zimmer, Lena Lampe, Dimitra Vlachopoulou, Matthias Totzeck, Tienush Rassaf, Raluca I. Mincu   +6 more
wiley   +1 more source

Atrial cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 727-729, April 2025.
Wojciech Kosmala, Monika Przewłocka‐Kosmala   +1 more
wiley   +1 more source

Cardiotoxicity of BRAF/MEK inhibitors

British Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe, Valerie Lohner, Kevin Terre, Thomas Riffelmacher, Roman Pfister   +4 more
wiley   +1 more source

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

British Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß, Paul Goerke, Malte Kelm, Amin Polzin   +3 more
wiley   +1 more source